Bausch & Lomb has acquired a licence to pair Brien Holden Vision Institute’s (BHVI) novel contact lens design with its own contact lens technologies to develop potential treatments to slow the progression of myopia in children.
Additionally, the company has acquired a licence from Eyenovia, Inc. in the United States and Canada, to develop and commercialise an investigational microdose formulation of atropine ophthalmic solution to reduce paediatric myopia progression in children aged three to 12.
“We are excited to leverage cutting-edge contact lens design technology from the renowned ophthalmic research organisation BHVI with our leading lens technologies so that we can research potential new treatment options for myopia, which continues to become more prevalent around the world,” said Joseph C. Papa, Chairman and CEO, Bausch Health. “As evidenced by both of our new exclusive licenses for different potential treatments for myopia, Bausch & Lomb remains committed to finding new approaches to treating this condition for as long as there is a need.”
Frank Back, Chairman, BHVI said, “For decades, BHVI has sought solutions to fulfill the unmet needs in the ophthalmic space by innovating commercially relevant technologies, including those specifically developed to help with myopia control. Bausch & Lomb’s long-standing position as a leader and innovator in eye health makes it the ideal choice for a partner, and we look forward to helping improve the vision of people with myopia around the world through their use of this contact lens design.”
